An Ensemble AI Model for RET Alteration Detection Using H&E Images as a Putative Screening Tool for More Efficient Genomic Alteration Detection-Reference-Cited by-同舟云学术

An Ensemble AI Model for RET Alteration Detection Using H&E Images as a Putative Screening Tool for More Efficient Genomic Alteration Detection

Published:2024-08-01 Issue:4 Volume:1 Page:216-227
ISSN:2993-091X
Container-title:AI in Precision Oncology
language:en
Short-container-title:AI in Precision Oncology

Author:

Bairavi Krishna¹,Kechavarzi Bobak²³,Abadi Arkan²,Mu Xinying¹,Credille Kelly M.²,Marella Narasimha²,Sireci Nino²,Mathews Michael D.²,Grinvalds Ross²,Klopfleisch Robert¹⁴,Colarusso Thomas¹,Puig Oscar²⁵,Chittenden Thomas W.¹⁶⁷,De Souza Andrea²⁸,Jerusalmi Alan¹^ORCID

Affiliation:

1. BioAI Health, Goffstown, New Hampshire, USA.

2. Eli Lilly, Indianapolis, Indiana, USA.

3. Currently Cleveland Clinic, Cleveland, Ohio, USA.

4. Institute of Veterinary Pathology, Freie Universitaet, Berlin, Germany.

5. Currently Nucleai, Chicago, Illinois, USA.

6. Digital Environment Research Institute, Queen Mary University of London, London, UK.

7. Present address: BullFrog AI, Gaithersburg, MD, USA.

8. Present address: Consulting for IonQ and Qubit Pharmaceuticals, USA.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/aipo.2024.0015

Reference39 articles.

1. Artificial intelligence is improving the detection of lung cancer

2. New driver mutations in non-small-cell lung cancer

3. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

4. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)